Royal Bank Of Canada reaffirmed their sector perform rating on shares of Valeant Pharmaceuticals Intl Inc (TSE:VRX) in a research note issued to investors on Monday morning, StockTargetPrices.com reports. Royal Bank Of Canada currently has a C$46.00 price objective on the specialty pharmaceutical company’s stock.
Several other research analysts also recently commented on VRX. TD Securities dropped their price objective on shares of Valeant Pharmaceuticals Intl from C$45.00 to C$38.00 in a report on Wednesday, June 8th. Scotiabank dropped their price objective on shares of Valeant Pharmaceuticals Intl from C$35.00 to C$32.00 and set a sector perform rating for the company in a report on Monday, July 25th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and an average price target of C$38.67.
Shares of Valeant Pharmaceuticals Intl (TSE:VRX) opened at 32.95 on Monday. Valeant Pharmaceuticals Intl has a 52-week low of $24.32 and a 52-week high of $240.40. The firm has a 50-day moving average price of $36.76 and a 200-day moving average price of $35.98. The stock’s market capitalization is $11.45 billion.
About Valeant Pharmaceuticals Intl
Valeant Pharmaceuticals International, Inc is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries.
Receive News & Ratings for Valeant Pharmaceuticals Intl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl Inc and related companies with MarketBeat.com's FREE daily email newsletter.